167 related articles for article (PubMed ID: 32495283)
1. ASO Author Reflections: A Standard Set of Value-Based Patient-Centered Outcomes for Pancreatic Carcinoma: An International Delphi Survey.
Pessaux P; Cherkaoui Z
Ann Surg Oncol; 2020 Dec; 27(Suppl 3):773-774. PubMed ID: 32495283
[No Abstract] [Full Text] [Related]
2. A Standard Set of Value-Based Patient-Centered Outcomes for Pancreatic Carcinoma: An International Delphi Survey.
Cherkaoui Z; González C; Wakabayashi T; Delattre B; Léost E; Serra S; Huppertz J; Klein F; Stéphan M; Meyer JM; Schaff A; Martinis E; Bangoura E; Kieffer S; Blanès S; Haddad E; De Guio G; Felli E; Pernot S; Marescaux J; Mutter D; Lugiez C; Pessaux P;
Ann Surg Oncol; 2021 Feb; 28(2):1069-1078. PubMed ID: 32514806
[TBL] [Abstract][Full Text] [Related]
3. ASO Author Reflections: Unlocking the Value of Inpatient Palliative Care for Patients with Pancreatic Cancer.
Kim S; Chervu N; Premji A; Mallick S; Verma A; Ali K; Benharash P; Donahue T
Ann Surg Oncol; 2024 Feb; 31(2):1362-1363. PubMed ID: 38063981
[No Abstract] [Full Text] [Related]
4. ASO Author Reflections: Frailty in Pancreatic Cancers.
Zhang F; Yan Y; Ge C
Ann Surg Oncol; 2024 Jan; 31(1):545. PubMed ID: 37843665
[No Abstract] [Full Text] [Related]
5. ASO Author Reflections: Identification of Prognostic Factors for Stage-III Pancreatic Ductal Adenocarcinoma patients.
Chattopadhyay A; Wu CH; Tien YW; Lu TP
Ann Surg Oncol; 2022 Mar; 29(3):1616-1617. PubMed ID: 34802101
[No Abstract] [Full Text] [Related]
6. ASO Author Reflections: Real Prevalence of Occult Cancer Cells in Peritoneal Lavage in Patients with Pancreatic Ductal Adenocarcinoma.
Suenaga M; Fujii T
Ann Surg Oncol; 2020 Dec; 27(Suppl 3):893-894. PubMed ID: 32812111
[No Abstract] [Full Text] [Related]
7. ASO Author Reflections: Disparities in NCCN Guideline-Compliant Care for Patients with Early-Stage Pancreatic Adenocarcinoma at Minority-Serving Versus Non-minority-Serving Hospitals.
Lima HA; Moazzam Z; Pawlik TM
Ann Surg Oncol; 2023 Jul; 30(7):4373-4374. PubMed ID: 36808592
[No Abstract] [Full Text] [Related]
8. ASO Author Reflections: Re-Excision for Ductal Carcinoma In Situ: Who Is at Risk?
Lamb LR; Bahl M
Ann Surg Oncol; 2021 Mar; 28(3):1398-1399. PubMed ID: 32946015
[No Abstract] [Full Text] [Related]
9. ASO Author Reflections: Long-Term Outcomes After Surgical Resection of Pancreatic Metastases from Renal Clear-Cell Carcinoma.
Malleo G; Salvia R; Allen PJ; Butturini G
Ann Surg Oncol; 2021 Jun; 28(6):3109-3110. PubMed ID: 33560488
[No Abstract] [Full Text] [Related]
10. ASO Author Reflections: Tumor-Infiltrating Platelets Predict Postsurgical Survival in Patients with Pancreatic Ductal Adenocarcinoma.
Zhang SR; Li H; Wang WQ; Liu L; Yu XJ
Ann Surg Oncol; 2018 Dec; 25(13):3994-3995. PubMed ID: 30315385
[No Abstract] [Full Text] [Related]
11. ASO Author Reflections: Health Disparities in Pancreatic Cancer.
Lutfi W; Hogg ME
Ann Surg Oncol; 2018 Dec; 25(Suppl 3):824-825. PubMed ID: 30377920
[No Abstract] [Full Text] [Related]
12. ASO Author Reflections: Role of SOX9 Transcription Factor in Pancreatic Neoplasms.
Turner K; Gnerlich JL
Ann Surg Oncol; 2019 Dec; 26(Suppl 3):567-568. PubMed ID: 30680476
[No Abstract] [Full Text] [Related]
13. ASO Author Reflections: Tumor-Infiltrating NETs are New Biomarkers to Predict Postsurgical Survival for Patients with Pancreatic Ductal Adenocarcinoma.
Jin W; Xu HX; Yu XJ; Liu L
Ann Surg Oncol; 2019 Dec; 26(Suppl 3):571-572. PubMed ID: 30710182
[No Abstract] [Full Text] [Related]
14. ASO Author Reflections: Do Distinct Patterns of Recurrence Impact the Prognosis of Patients With Resected Pancreatic Ductal Adenocarcinoma?
Groot VP; Wolfgang CL; He J
Ann Surg Oncol; 2018 Dec; 25(Suppl 3):806-807. PubMed ID: 30298312
[No Abstract] [Full Text] [Related]
15. ASO Author Reflections: Even in Pancreatic Cancer, not all N Diseases are Created Equal.
Nizri E; Lahat G; Klausner J
Ann Surg Oncol; 2018 Dec; 25(Suppl 3):804-805. PubMed ID: 30284129
[No Abstract] [Full Text] [Related]
16. ASO Author Reflections: The Naples Prognostic Score Predicts Long-Term Survival in Patients with Resected Pancreatic Cancer.
Nakagawa N; Yamada S; Kodera Y
Ann Surg Oncol; 2020 Mar; 27(3):896-897. PubMed ID: 31848821
[No Abstract] [Full Text] [Related]
17. ASO Author Reflections: Lymphocyte-to-monocyte ratio as prognostic biomarker in pancreatic ductal adenocarcinoma.
Kubota K; Shimizu A; Soejima Y
Ann Surg Oncol; 2022 Feb; 29(2):1449-1450. PubMed ID: 34618246
[No Abstract] [Full Text] [Related]
18. ASO Author Reflections: Progression after Resection of Noninvasive or Microinvasive Intraductal Papillary Mucinous Neoplasms.
Al Efishat M; Allen PJ
Ann Surg Oncol; 2018 Dec; 25(Suppl 3):822-823. PubMed ID: 30324467
[No Abstract] [Full Text] [Related]
19. ASO Author Reflections: Pancreatic Invasion is a Crucial Independent Prognostic Factor in Duodenal Carcinoma.
Nitta N; Ohgi K; Sugiura T; Okamura Y; Ito T; Yamamoto Y; Ashida R; Sasaki K; Uesaka K
Ann Surg Oncol; 2020 Oct; 27(11):4561. PubMed ID: 32462525
[No Abstract] [Full Text] [Related]
20. ASO Author Reflections: Tumor Biology and Safe Surgery Remain Major Determinants of Survival After Resection of Pancreatic Adenocarcinoma.
Newhook TE; Tzeng CD
Ann Surg Oncol; 2021 Mar; 28(3):1570-1571. PubMed ID: 32880772
[No Abstract] [Full Text] [Related]
[Next] [New Search]
